← Back to Search

Anti-tumor antibiotic

170 mg/m2 aldoxorubicin for Soft Tissue Sarcoma

Phase 1 & 2
Waitlist Available
Research Sponsored by ImmunityBio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 17 months
Awards & highlights

Summary

This is a Phase 1 open-label study to study the safety and activity of aldoxorubicin with ifosfamide/mesna in subjects with metastatic, advanced, unresectable soft tissue sarcoma.

Eligible Conditions
  • Soft Tissue Sarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~17 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 17 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Adverse Events in Participants
Secondary study objectives
Tumor Response

Trial Design

2Treatment groups
Experimental Treatment
Group I: 250 mg/m2 aldoxorubicinExperimental Treatment1 Intervention
Group II: 170 mg/m2 aldoxorubicinExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
250 mg/m2 aldoxorubicin
2014
Completed Phase 2
~100
170 mg/m2 aldoxorubicin
2014
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

ImmunityBio, Inc.Lead Sponsor
66 Previous Clinical Trials
4,687 Total Patients Enrolled
CytRxLead Sponsor
21 Previous Clinical Trials
1,521 Total Patients Enrolled
Dan Levitt, M.D.Study DirectorCytRx Coporation
1 Previous Clinical Trials
30 Total Patients Enrolled
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top